Nextcure Stock Analysis
| NXTC Stock | USD 1.29 0.01 0.77% |
NextCure is undervalued with Real Value of 2.53 and Target Price of 6.33. The main objective of NextCure stock analysis is to determine its intrinsic value, which is an estimate of what NextCure is worth, separate from its market price. There are two main types of NextCure's stock analysis: fundamental analysis and technical analysis.
The NextCure stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and NextCure's ongoing operational relationships across important fundamental and technical indicators.
NextCure |
NextCure Stock Analysis Notes
About 58.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.48. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NextCure has Price/Earnings To Growth (PEG) ratio of 0.03. The entity recorded a loss per share of 2.08. The firm had not issued any dividends in recent years. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Nextcure operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people. To find out more about NextCure contact Michael MSBA at 240 399 4900 or learn more at https://www.nextcure.com.NextCure Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. NextCure's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding NextCure or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| NextCure generated a negative expected return over the last 90 days | |
| NextCure may become a speculative penny stock | |
| NextCure has high historical volatility and very poor performance | |
| NextCure has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (62.72 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NextCure has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Feigal Ellen of 14250 shares of NextCure subject to Rule 16b-3 |
NextCure Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NextCure previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
NextCure Largest EPS Surprises
Earnings surprises can significantly impact NextCure's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-03-04 | 2020-12-31 | -0.6 | -0.54 | 0.06 | 10 | ||
2024-11-04 | 2024-09-30 | -0.34 | -0.41 | -0.07 | 20 | ||
2022-05-05 | 2022-03-31 | -0.67 | -0.74 | -0.07 | 10 |
NextCure Stock Institutional Investors
| Shares | Acuitas Investments, Llc | 2024-06-30 | 323.3 K | Federated Hermes Inc | 2024-09-30 | 321.5 K | Citadel Advisors Llc | 2024-06-30 | 289.1 K | Bml Capital Management Llc | 2024-09-30 | 276.5 K | Cardiff Park Advisors, Llc | 2024-06-30 | 262 K | Hudson Bay Capital Management Lp | 2024-06-30 | 203.8 K | Geode Capital Management, Llc | 2024-06-30 | 195.9 K | Macquarie Group Ltd | 2024-06-30 | 150 K | Sio Capital Management, Llc | 2024-06-30 | 130 K | Logos Global Management Lp | 2024-06-30 | 5 M | Sofinnova Ventures | 2024-06-30 | 2.7 M |
NextCure Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.69 M.NextCure Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.49) | (0.51) | |
| Return On Equity | (0.55) | (0.52) |
Management Efficiency
NextCure has return on total asset (ROA) of (0.3109) % which means that it has lost $0.3109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5475) %, meaning that it created substantial loss on money invested by shareholders. NextCure's management efficiency ratios could be used to measure how well NextCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, NextCure's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 200.8 M, whereas Net Tangible Assets are forecasted to decline to about 173.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.11 | 4.87 | |
| Tangible Book Value Per Share | 4.11 | 4.87 | |
| Enterprise Value Over EBITDA | (0.43) | (0.45) | |
| Price Book Value Ratio | 0.28 | 0.29 | |
| Enterprise Value Multiple | (0.43) | (0.45) | |
| Price Fair Value | 0.28 | 0.29 | |
| Enterprise Value | 25.3 M | 24 M |
Understanding the operational decisions made by NextCure management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.791 | Return On Assets (0.31) | Return On Equity (0.55) |
Technical Drivers
As of the 21st of November, NextCure secures the Standard Deviation of 3.53, risk adjusted performance of (0.05), and Mean Deviation of 2.55. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NextCure, as well as the relationship between them.NextCure Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. NextCure middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for NextCure. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
NextCure Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NextCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on NextCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NextCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NextCure Outstanding Bonds
NextCure issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NextCure uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NextCure bonds can be classified according to their maturity, which is the date when NextCure has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NextEra Energy Operating Corp BondUS65342QAB86 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| NextEra Energy Operating Corp BondUS65342QAL68 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
NextCure Predictive Daily Indicators
NextCure intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NextCure stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
NextCure Forecast Models
NextCure's time-series forecasting models are one of many NextCure's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary NextCure's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About NextCure Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how NextCure prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling NextCure shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as NextCure. By using and applying NextCure Stock analysis, traders can create a robust methodology for identifying NextCure entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.47) | (1.55) | |
| Operating Profit Margin | (1.66) | (1.74) | |
| Net Loss | (1.33) | (1.40) | |
| Gross Profit Margin | 0.90 | 0.80 |
Current NextCure Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. NextCure analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. NextCure analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 6.33 | Buy | 3 | Odds |
Most NextCure analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand NextCure stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of NextCure, talking to its executives and customers, or listening to NextCure conference calls.
NextCure Stock Analysis Indicators
NextCure stock analysis indicators help investors evaluate how NextCure stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading NextCure shares will generate the highest return on investment. By understating and applying NextCure stock analysis, traders can identify NextCure position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 26.6 M | |
| Common Stock Shares Outstanding | 27.8 M | |
| Total Stockholder Equity | 114.4 M | |
| Property Plant And Equipment Net | 13.4 M | |
| Cash And Short Term Investments | 108.3 M | |
| Cash | 13.1 M | |
| Accounts Payable | 2.3 M | |
| Net Debt | -6.5 M | |
| 50 Day M A | 1.3656 | |
| Total Current Liabilities | 6.9 M | |
| Other Operating Expenses | 67.6 M | |
| Non Current Assets Total | 15.3 M | |
| Non Currrent Assets Other | 1.9 M | |
| Stock Based Compensation | 8.2 M |
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |